[1]
|
Zesiewicz, T.A., Sullivan, K.L. and Hauser, R.A. (2007) Levodopa-Induced Dyskinesia in Parkinson’s Disease: Epide-miology, Etiology, and Treatment. Current Neurology and Neuroscience Reports, 7, 302-310.
https://doi.org/10.1007/s11910-007-0046-y
|
[2]
|
Encarnacion, E.V. and Hauser, R.A. (2008) Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life and Treatments. European Neurology, 60, 57-66. https://doi.org/10.1159/000131893
|
[3]
|
Cao, X.B., Guan, Q., Xu, Y., et al. (2006) Mechanism of Over-Activation in Direct Pathway Mediated by Dopamine D1 Receptor in Rats with Levodopa-Induced Dyskinesia. Neuroscience Bulletin, 22, 159-164.
|
[4]
|
Fabbrini, G., Brotchie, J.M., Grandas, F., et al. (2007) Levodopa-Induced Dyskinesias. Movement Disorders, 22, 1379- 1389. https://doi.org/10.1002/mds.21475
|
[5]
|
巴茂文, 刘振国, 孔敏, 等. 左旋多巴诱发帕金森病大鼠异动症模型的建立和评价[J]. 上海交通大学学报(医学版), 2006, 26(7): 810-812.
|
[6]
|
包新民, 舒思云. 大鼠脑立体定位图谱[M]. 北京: 人民卫生出版社, 1991: 53.
|
[7]
|
Carman, L.S., Gage, G.H. and Shults, C.W. (1991) Partial Lesion of the Substantia Nigra: Relation between Extent of 1esion and Rota-tional Behavior. Brain Research, 553, 275-283.
|
[8]
|
曹学兵, 孙圣刚, 徐岩, 等. 左旋多巴治疗帕金森病诱发异动症的实验研究[J]. 中华医学杂志, 2004, 84(6): 505-507.
|
[9]
|
李丹, 黄议腺, 王晓军, 等. 左旋多巴诱发异动症6-羟基多巴帕金森病大鼠模型的建立及行为学评价[J]. 苏州大学学报: 医学版, 2010, 30(2): 236-239.
|
[10]
|
叶青, 周洁, 袁灿兴. 滋肾平颤颗粒对异动症大鼠行为学及黑质纹状体DAT和VMAT2基因表达的影响[J]. 江苏中医药, 2014, 46(4): 74-76.
|
[11]
|
张旺明, 蔡颖谦, 徐如祥, 等. 帕金森病大鼠模型尾壳核多巴胺D2受体活性变化研究[J]. 中华神经外科疾病研究杂志, 2002, 1(3): 266-268.
|
[12]
|
Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., et al. (2000) Pathophysiology of Levodopa-Induced Dyskinesias in Parkinson’s Disease: Problems with the Current Model. Discussion. Annals of Neurology, 47, S22-S34.
|
[13]
|
Utsumi, H., Okuma, Y., Kano, O., et al. (2013) Evaluation of the Efficacy of Pramipexole for Treating Levodopa-In- duced Dyskinesia in Patients with Parkinson’s Disease. Internal Medicine, 52, 325-332.
|
[14]
|
Brotchie, J.M., Lee, J. and Venderova, K. (2005) Levodopa-Induced Dyskinesia in Parkin-son, s Disease. Journal of Neural Transmission, 112, 359-391. https://doi.org/10.1007/s00702-004-0251-7
|
[15]
|
Mela, F., Marti, M., Bido, S., et al. (2012) In Vivo Evidence for a Dif-ferential Contribution of Striatal and Nigral D1 and D2 Receptors to L-DOPA Induced Dyskinesia and the Accompany-ing Surge of Nigral Amino Acid Levels. Neurobiology of Disease, 45, 573-582.
|
[16]
|
Santini, E., Valjent, E. and Fisone, G. (2008) Parkinson’s Disease: Levodopa-Induced Dyskinesia and Signal Transduction. The FEBS Journal, 275, 1392-1399. https://doi.org/10.1111/j.1742-4658.2008.06296.x
|
[17]
|
周洁, 叶青, 袁灿兴. 熟地平颤汤治疗帕金森氏病的随机对照研究[J]. 中华中医药学刊, 2014, 32(6): 1395-1397.
|
[18]
|
Ye, Q., Yuan, X.-L., Zhou, J., Yuan, C. and Yang, X.-M. (2014) Effect of Zishenpingchan Granule on Neurobehavioral Manifestations and the Activity and Gene Expression of Striatal Dopamine D1 and D2 Receptors of Rats with Levodopa-Induced Dyskinesias. Evi-dence-Based Complementary and Alternative Medicine, 2014, Article ID: 342506.
|
[19]
|
Ye, Q., Yuan, X.-L., He, J., et al. (2016) Anti-Apoptotic Effect of Shudipingchan Granule in the Substantia Nigra of Rat Models of Parkinson’s Dis-ease. Neural Regeneration Research, 11, 1625-1632.
https://doi.org/10.4103/1673-5374.193242
|